nhf

NHF, or Non-Hodgkin's Follicular Lymphoma, is a type of cancer that originates in the lymphatic system, which is part of the body's immune system. It is characterized by the abnormal growth of B cells, which are a type of white blood cell. NHF is classified as a B-cell lymphoma and is further categorized into three subtypes: grade 1, grade 2, and grade 3, based on the degree of malignancy and the presence of specific genetic abnormalities.

The most common subtype is grade 1, which is often indolent and can be slow-growing. Grade 2 and grade 3 are more aggressive and can progress more rapidly. The disease typically affects older adults, with a median age at diagnosis around 65 years. Symptoms may include swollen lymph nodes, fatigue, weight loss, and fever.

Diagnosis of NHF usually involves a combination of physical examination, blood tests, imaging studies, and biopsy of the affected lymph nodes. Treatment options depend on the subtype and stage of the disease, and may include watchful waiting, chemotherapy, radiation therapy, or a combination of these. In some cases, stem cell transplant may be recommended for patients with relapsed or refractory disease.

Prognosis for NHF varies depending on the subtype and stage at diagnosis. Grade 1 NHF has a relatively good prognosis, with a 5-year survival rate of around 80-90%. Grade 2 and grade 3 NHF have a poorer prognosis, with 5-year survival rates of around 60-70% and 40-50%, respectively. However, advances in treatment and supportive care have improved outcomes for many patients with NHF.